{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:52:24Z","timestamp":1773262344426,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,10,17]],"date-time":"2012-10-17T00:00:00Z","timestamp":1350432000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s00277-012-1594-z","type":"journal-article","created":{"date-parts":[[2012,10,17]],"date-time":"2012-10-17T14:39:59Z","timestamp":1350484799000},"page":"191-198","source":"Crossref","is-referenced-by-count":65,"title":["Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload"],"prefix":"10.1007","volume":"92","author":[{"given":"F.","family":"Nolte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"H\u00f6chsmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Giagounidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"L\u00fcbbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Haase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"L\u00fcck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Gattermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Taupitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Baier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Leismann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Junkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Schumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. K.","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Schrezenmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,17]]},"reference":[{"key":"1594_CR1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2217\/fon.09.175","volume":"6","author":"F Nolte","year":"2010","unstructured":"Nolte F, Hofmann WK (2010) Molecular mechanisms involved in the progression of myelodysplastic syndrome. Future Oncol 6:445\u2013455","journal-title":"Future Oncol"},{"key":"1594_CR2","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ajh.21249","volume":"83","author":"JM Kao","year":"2008","unstructured":"Kao JM, McMillan A, Greenberg PL (2008) International MDS risk analysis workshop (IMRAW)\/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 83:765\u2013770","journal-title":"Am J Hematol"},{"key":"1594_CR3","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.leukres.2011.06.001","volume":"35","author":"J Neukirchen","year":"2011","unstructured":"Neukirchen J, Schoonen WM, Strupp C et al (2011) Incidence and prevalence of myelodysplastic syndromes: data from the Dusseldorf MDS-registry. Leuk Res 35:1591\u20131596","journal-title":"Leuk Res"},{"key":"1594_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-010-1091-1","volume":"90","author":"N Gattermann","year":"2011","unstructured":"Gattermann N, Rachmilewitz EA (2011) Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol 90:1\u201310","journal-title":"Ann Hematol"},{"key":"1594_CR5","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(00)02357-6","volume":"355","author":"B Modell","year":"2000","unstructured":"Modell B, Khan M, Darlison M (2000) Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 355:2051\u20132052","journal-title":"Lancet"},{"key":"1594_CR6","first-page":"1187","volume":"89","author":"C Borgna-Pignatti","year":"2004","unstructured":"Borgna-Pignatti C, Rugolotto S, De Stefano P et al (2004) Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89:1187\u20131193","journal-title":"Haematologica"},{"key":"1594_CR7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1600-0609.2007.00842.x","volume":"78","author":"M Takatoku","year":"2007","unstructured":"Takatoku M, Uchiyama T, Okamoto S et al (2007) Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity\/mortality. Eur J Haematol 78:487\u2013494","journal-title":"Eur J Haematol"},{"issue":"Suppl 3","key":"1594_CR8","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0145-2126(07)70460-5","volume":"31","author":"HA Leitch","year":"2007","unstructured":"Leitch HA (2007) Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 31(Suppl 3):S7\u2013S9","journal-title":"Leuk Res"},{"key":"1594_CR9","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.leukres.2009.12.004","volume":"34","author":"C Rose","year":"2010","unstructured":"Rose C, Brechignac S, Vassilief D et al (2010) Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 34:864\u2013870","journal-title":"Leuk Res"},{"key":"1594_CR10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.6004\/jnccn.2011.0007","volume":"9","author":"DP Steensma","year":"2011","unstructured":"Steensma DP (2011) The role of iron chelation therapy for patients with myelodysplastic syndromes. J Natl Compr Canc Netw 9:65\u201375","journal-title":"J Natl Compr Canc Netw"},{"key":"1594_CR11","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s002280000251","volume":"56","author":"R Arboretti","year":"2001","unstructured":"Arboretti R, Tognoni G, Alberti D (2001) Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemiological survey. Eur J Clin Pharmacol 56:915\u2013922","journal-title":"Eur J Clin Pharmacol"},{"key":"1594_CR12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2141.1992.tb06411.x","volume":"80","author":"PD Jensen","year":"1992","unstructured":"Jensen PD, Jensen IM, Ellegaard J (1992) Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol 80:121\u2013124","journal-title":"Br J Haematol"},{"key":"1594_CR13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1365-2141.1996.d01-1795.x","volume":"94","author":"PD Jensen","year":"1996","unstructured":"Jensen PD, Heickendorff L, Pedersen B et al (1996) The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 94:288\u2013299","journal-title":"Br J Haematol"},{"key":"1594_CR14","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.leukres.2010.11.027","volume":"35","author":"R Guariglia","year":"2011","unstructured":"Guariglia R, Martorelli MC, Villani O et al (2011) Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. Leuk Res 35:566\u2013570","journal-title":"Leuk Res"},{"key":"1594_CR15","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3324\/haematol.2011.048546","volume":"97","author":"N Gattermann","year":"2012","unstructured":"Gattermann N, Finelli C, Della Porta M et al (2012) Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients. Haematologica 97:1364\u20131371","journal-title":"Haematologica"},{"key":"1594_CR16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00277-012-1481-7","volume":"91","author":"M Breccia","year":"2012","unstructured":"Breccia M, Finsinger P, Loglisci G et al (2012) Deferasirox treatment for myelodysplastic syndromes: \u201creal-life\u201d efficacy and safety in a single-institution patient population. Ann Hematol 91:1345\u20131349","journal-title":"Ann Hematol"},{"key":"1594_CR17","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1200\/JCO.2010.34.1222","volume":"30","author":"AF List","year":"2012","unstructured":"List AF, Baer MR, Steensma DP et al (2012) Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol 30:2134\u20132139","journal-title":"J Clin Oncol"},{"key":"1594_CR18","first-page":"3826","volume":"114","author":"J Hartmann","year":"2009","unstructured":"Hartmann J, Sinzig U, Wulf G et al (2009) Significant suppression of the colony forming capacity of erythroid progenitors by iron overload in patients with MDS and sequential analyses of BFU-E under chelation therapy. ASH Annu Meet Abstr 114:3826","journal-title":"ASH Annu Meet Abstr"},{"key":"1594_CR19","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.leukres.2010.06.013","volume":"34","author":"PL Greenberg","year":"2010","unstructured":"Greenberg PL, Koller CA, Cabantchik ZI et al (2010) Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res 34:1560\u20131565","journal-title":"Leuk Res"},{"key":"1594_CR20","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","volume":"107","author":"MD Cappellini","year":"2006","unstructured":"Cappellini MD, Cohen A, Piga A et al (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107:3455\u20133462","journal-title":"Blood"},{"key":"1594_CR21","first-page":"873","volume":"91","author":"A Piga","year":"2006","unstructured":"Piga A, Galanello R, Forni GL et al (2006) Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91:873\u2013880","journal-title":"Haematologica"},{"key":"1594_CR22","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2004-01-0177","volume":"105","author":"TG St Pierre","year":"2005","unstructured":"St Pierre TG, Clark PR, Chua-anusorn W et al (2005) Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105:855\u2013861","journal-title":"Blood"},{"key":"1594_CR23","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.leukres.2010.03.009","volume":"34","author":"N Gattermann","year":"2010","unstructured":"Gattermann N, Finelli C, Porta MD et al (2010) Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 34:1143\u20131150","journal-title":"Leuk Res"},{"key":"1594_CR24","first-page":"634","volume":"112","author":"AF List","year":"2008","unstructured":"List AF, Baer MR, Steensma D et al (2008) Iron chelation with deferasirox (Exjade(R)) improves iron burden in patients with myelodysplastic syndromes (MDS). ASH Annu Meet Abstr 112:634","journal-title":"ASH Annu Meet Abstr"},{"key":"1594_CR25","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1182\/blood-2010-01-261289","volume":"116","author":"JW Lee","year":"2010","unstructured":"Lee JW, Yoon SS, Shen ZX et al (2010) Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood 116:2448\u20132454","journal-title":"Blood"},{"key":"1594_CR26","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.21269","volume":"83","author":"JM Bennett","year":"2008","unstructured":"Bennett JM (2008) Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 83:858\u2013861","journal-title":"Am J Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-012-1594-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-012-1594-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-012-1594-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T05:50:28Z","timestamp":1559022628000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-012-1594-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,17]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["1594"],"URL":"https:\/\/doi.org\/10.1007\/s00277-012-1594-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,17]]}}}